Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigm for lung cancer in recent years. These strategies consist of neutralizing antibodies against negative regulators of immune function, most notably cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death...

Descripción completa

Detalles Bibliográficos
Autores principales: Principe, Daniel R., Chiec, Lauren, Mohindra, Nisha A., Munshi, Hidayatullah G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204014/
https://www.ncbi.nlm.nih.gov/pubmed/34141625
http://dx.doi.org/10.3389/fonc.2021.684098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204014/
https://www.ncbi.nlm.nih.gov/pubmed/34141625
http://dx.doi.org/10.3389/fonc.2021.684098

Ejemplares similares